Clinical trial NCT04795310: Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia
Official title: A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser and Intense Pulsed Light With Different Wavelength Bands in the Treatment of Facial Telangiectasia: a Retrospective, Self-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Telangiectasia
Keywords: Facial Telangiectasia
Pulsed dye laser (PDL)
Intense Pulsed Light
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2021-03-12
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. Facial telangiectasia is one of the common skin vascular lesions characterized by dilated cutaneous vasculatures in the skin surface or mucous membranes. Lesions are generally sensitive to exposure of cold, heat and sun. Those distinct small dilated blood vessels are cosmetically disfiguring for patients which require an effective solution. The traditional management options for facial telangiectasia include cryotherapy, CO2 laser, topical agent, oral estrogens, electrosurgery, and radioactive treatment. However, inadequate outcomes and severe adversaries are the major concerns to patients and physicians.
2. Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis.

   The intense pulsed light source is an alternative or supplement to the already existing laser devices that are part of the laser surgeon's repertoire. The broad wavelength spectrum and variable pulse duration allow greater penetration depths to be reached without damaging surrounding tissue and thus enhance the versatility of this system.
3. This study aims to compare the clearance efficacy of facial telangiectasia using PDL (595nm) with IPL configured by various wavelength bands, including M22 vascular filter (530-650nm and 900-1200nm), M22 560 (560-1200nm), M22 590 (590-1200nm) .

Detailed description: Detailed Description has not been entered.

Eligibility criteria: Inclusion Criteria:

* Subjects must be clinically diagnosed with facial telangiectasia
* No other external treatment was performed before the injury was treated

Exclusion Criteria:

* subjects with a recent history of exposure to sunlight
* subjects allergic to topical anesthesia
* subjects with scar constitution
* subjects with skin malignant tumors or precancerous lesions
* subjects with diabetes, heart disease, epilepsy, connective tissue disease, etc
* subjects who Pregnant or breast feeding
* subjects with recent skin infections (such as viruses, bacteria, etc.)
* other methods are being used to treat subjects with similar diseases
* subject who have taken isotretinoin A in the past year
* subject with facial dermatitis

Primary outcomes:
measure: Severity index of facial telangiectasia
timeFrame: 6months
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
affiliation: Dermatology Derpartment of Xijing Hospital
name: Gang Wang, Prof
role: PRINCIPAL_INVESTIGATOR
References: